Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the Pharma & Biotech edition of the IP Think Tank Global Week in Review by subscribing by email, or selecting ‘all posts’ or ‘Pharma, Biotech & Chem’ for the RSS option at the Subscribe page: http://thinkipstrategy.com/subscribe/

 

Highlights this week included:

Biaxin (Clarithromycin) – US: New standard for materiality: Abbott Laboratories v. Sandoz, Inc (Law360) (Hal Wegner) (Patently-O) (Patent Prospector) (PLI)

Levaquin (Levofloxacin) – UK: Levofloxacin SPC valid: Generics (UK) Ltd v Daiichi Pharmaceutical Co Ltd & Anor (IPKat) (The SPC blog)

Sustiva (Efavirenz) – Brazil: Compulsory licensed Efavirenz will be manufactured by public Brazilian laboratories by end of 2008 (IP tango)

 

A patent question of patents: Prof T Pogge’s ‘Health Impact Fund’ alternative licensing system (Patent Baristas)

Commissioner John Doll at BIO IP Counsel Committee: ‘We’d allow every patent application if it just met the requirements’ (Patent Baristas)

EU: European drug industry calls on EU to curb parallel trading of pharmaceuticals (FDA Law Blog)

India: Government opposes new definition of counterfeit drugs (Spicy IP)

UK: BioIndustry Association to co-market with UTEK division (Intellectual Property Marketing Advisor)

US: In re TziporiCAFC affirms BPAI determination of obviousness for patent relating to antibodies that bind Shiga-like toxin II (SLT-II) (Hal Wegner) (Patent Docs)

US: Biologicsland – game tests knowledge about biogenerics (Patent Baristas)

US: Supreme Court agrees to hear patent case between Carlsbad Technology and HIF Bio to decide whether Federal Circuit has jurisdiction to review appeal of district court’s decision to remand case to state court (Managing Intellectual Property)

US: Intellectual property in a public health crisis (Patently-O)

 

Abilify (Aripiprazole) – US: Otsuka Pharmaceutical sues Apotex again over generic Abilify (Law360)

Actoplus Met (Metformin and Pioglitazone ) – US: Takeda, Mylan agree to dismiss claims related to one of four patents at issue in lawsuit over Mylan’s plans to develop generic Actoplus Met (Law360)

Arixtra (Fondaparinux) – US: Key Fondaparinux patent allowed by USPTO (GenericsWeb)

Biaxin (Clarithromycin) – US: New standard for materiality: Abbott Laboratories v. Sandoz, Inc (Law360) (Hal Wegner) (Patently-O) (Patent Prospector) (PLI)

Cipro (Ciprofloxacin) – US: CAFC finds no antitrust liability for Hatch-Waxman reverse payment settlements: In Re Ciproflaxacin Hydrochloride Antitrust Litigation (IP Law Observer)

Lescol (Fluvastatin) – US: Mylan confirms first-to-file patent challenge to Lescol by Novartis (SmartBrief)

Levaquin (Levofloxacin) – UK: Levofloxacin SPC valid: Generics (UK) Ltd v Daiichi Pharmaceutical Co Ltd & Anor (IPKat) (The SPC blog)

Opana (Oxymorphone) – US: Endo, Penwest sue Barr over Opana patents; Barr confirms challenge of Opana patent (GenericsWeb) (Law360) (SmartBrief)

Prazol (Omeprazole) – EU: Court of First Instance hands down in decision in Aventis Pharma SA v Office for Harmonisation in the Internal Market, Nycomed GmbH, an appeal involving a Community trade mark opposition to PRAZOL (IPKat)

Sustiva (Efavirenz) – Brazil: Compulsory licensed Efavirenz will be manufactured by public Brazilian laboratories by end of 2008 (IP tango)